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 Structured Abstract 
Objective: 
To determine whether long term (>48 months) symptomatic vertigo control is sustained in 
patients with Menière’s disease who were involved in a previous comparative trial of 
intratympanic methylprednisolone versus gentamicin. This study also aims to determine if 
the two treatment arms remain similar at long-term follow-up, as original trial results at 24 
months found no significant difference between drug treatments. 
Patients: 
Adult patients with definite unilateral refractory Menière’s disease, who previously received 
either intratympanic methylprednisolone or gentamicin.  
Intervention: 
A mail survey of patient’s symptoms was conducted to determine long-term follow-up 
results of trial participants who received random double-blind allocation of intratympanic 
injection of gentamicin (40mg/mL) versus methylprednisolone (62.5mg/mL). 
Outcome measures: 
Primary outcome: number of vertigo attacks in the 6 months prior to receiving this survey 
compared with the 6 months before the first trial injection. 
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Secondary outcomes: number of vertigo attacks over the previous 1 month; validated 
symptom questionnaire scores of tinnitus, dizziness, vertigo, aural fullness and functional 
disability. 
Results: 
Average follow-up was 70.8 months (standard deviation 17.0) from the first treatment 
injection in the previous trial. In an intention-to-treat analysis, vertigo attacks in the 6 
months prior to receiving the current survey reduced by 95% compared to baseline in both 
drug groups (both p<0.001). No significant difference between drugs was found for the 
primary and secondary outcomes. Eight participants (methylprednisolone =5 and 
gentamicin=3) required further injections for relapse after completing the original trial. 
Conclusion: 
Intratympanic methylprednisolone treatment provides effective long-lasting relief of 
vertigo, without the known inner-ear toxicity associated with gentamicin.  
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Introduction 
 
Menière’s disease is a chronic relapsing-remitting labyrinthine disease which significantly 
impacts patients’ quality of life, causing unpredictable attacks of vertigo, tinnitus, aural 
fullness and hearing loss. 1-31-31-3 
Randomized controlled trials have not demonstrated high-level evidence for non-invasive 
medical treatments (e.g. lifestyle counselling, low-salt diet, betahistine, diuretics, pressure 
pulse treatments), despite these being the first-line management commonly recommended 
by clinicians. 4-8  Although a recent international consensus document has supported 
intratympanic steroids (ITS) as appropriate second-line management when non-invasive 
treatments have failed, there has been much scepticism in the literature regarding steroid 
treatment over the last two decades.8-13 
Between 2009 and 2015 we carried out a prospective double-blind randomized comparative 
effectiveness trial of intratympanic injections of methylprednisolone versus gentamicin for 
unilateral refractory Menière’s disease with two year follow-up of vertigo control and audio-
vestibular function.14 The trial concluded that the primary outcome, vertigo control, was 
equal in both treatment arms, thus providing the first high level evidence in support of the 
use of intratympanic methylprednisolone.  
Based on the results of the original trial, the aim of the current study was to examine, in the 
same patient cohort, the effect of intratympanic treatment on refractory Menière’s disease 
symptoms, beyond the 1995 American Academy of Otolaryngology-Head and Neck Surgery 
(AAOHNS) guidelines on extended reporting (48 months from baseline).1 Our aim was to 
investigate whether the initial treatment effects were sustained, and whether any further 
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treatments were required. An examination of long-term treatment effects is pertinent in 
Menière’s disease because spontaneous relapse and remission is part of the natural history 
of the disease.15  
 
Materials and Methods 
Adult patients with definite unilateral Menière’s disease, refractory to standard non-
invasive treatments, who took part in a two year comparative effectiveness trial of 
intratympanic methylprednisolone versus gentamicin, completed in April 2015 9, were 
invited to complete a follow-up survey 48-95 months after baseline treatment and 
contacted by post, email and/or telephone.1,8,14 All patients provided written informed 
consent before enrolment in the original trial, which was approved by the London-Fulham 
Research Ethics Committee, Imperial College Joint Research Compliance Office, and the 
Medicines and Healthcare products Regulatory Agency. This study was done in accordance 
with the Declaration of Helsinki and International Council for Harmonisation’s Good Clinical 
Practice.  
In the original study patients were randomly assigned (1:1) and the trial was double blinded. 
The trial protocol involved two injections of either intratympanic methylprednisolone (62·5 
mg/mL) or gentamicin (40 mg/mL), the second injection 2 weeks after the first. Those with a 
diagnosis of migraine were excluded.  
After the trial period ended some patients went on to have further injections. These were 
carried out locally in many cases, did not necessarily follow trial injection protocol, and were 
un-blinded as patients had been told their original trial drug treatment by that time. 
Patients were allowed to refuse additional treatment as it would otherwise be deemed 
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unethical.  
 
 
Methylprednisolone was chosen rather than dexamethasone for scientific as well as 
practical reasons: higher endolymphatic concentrations, high perilymph concentrations, 
greater mineralocorticoid receptor binding and also high-dose dexamethasone (24 mg/mL) 
is not readily available in the UK and other countries.16-18 
 
 56 of the original 60 patients recruited were available to be contacted: one withdrew; 
another was lost to follow-up after the original study; two died of unrelated causes after the 
original study and before this follow-up survey. 
In the survey we asked patients “How many attacks of rotational vertigo (lasting more than 
20 minutes) have you had in the past 6 months?” and “How many attacks of rotational 
vertigo (lasting more than 20 minutes) have you had in the last month?”  Patients also 
scored the severity of their symptoms in the 1 month prior to receiving the current survey 
with the same validated questionnaires used in the original trial: Vertigo Symptom Scale 
short form (VSS)19, Dizziness Handicap Inventory (DHI)20, Functional Level Scale (FLS)1, 
Tinnitus Handicap Inventory (THI)21 and Aural Fullness Scale (AFS)22.  
Lastly, patients were asked whether further intratympanic injections or other treatments 
had been received after the original trial. In the original trial patients experiencing two or 
more vertigo episodes lasting more than 20 min (i.e. non-responders) received further 
injections, based on the view that depriving patients from further treatment with disabling 
vertigo attacks who did not respond to the initial programmed two injections would be 
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unethical. Following the end of the trial some patients similarly sought and received further 
injections either locally or through the original trial centres.  We recorded where possible 
(from patient questionnaire responses) whether further injections were the same as their 
original trial treatment or if they crossed over to the other drug group. The exact details of 
what drug regimen was used in their local ENT unit, and date administered, was not 
obtained. We are likewise unable to comment upon the amount of vertigo or other criteria 
used by different doctors for deciding when to perform repeat injections. 
 
Primary and secondary outcomes were the same as those from the original study except for 
hearing and speech discrimination levels, which were not included in this follow-up study.14 
The primary outcome was relief from vertigo (number of vertigo attacks in the 6 months 
prior to receiving the current survey (long-term follow-up) compared with the 6 months 
before the first injection (baseline). Secondary outcomes were number of vertigo attacks 
over 1 month at long-term follow-up compared with Baseline and symptom scores (VSS, 
DHI, FLS, THI and AFS). 
Repeated-measures general linear model ANOVA was used, with factor labels ‘drug’  
(methylprednisolone versus gentamicin), ‘time’ (baseline versus 24 months versus long-term 
follow-up), and drug x time interactions. Analyses were done in the intention-to-treat 
population and then per protocol. Paired t-tests were used to explore within group effects. 
Independent-samples t tests were used to assess differences between groups and chi-
square analysis to compare the number of patients given further intratympanic injections 
after baseline treatment.  Chi-square and exact tests were employed where relevant for 
categorical data. All analyses were done in SPSS, version 24. 
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Results  
46 patients (23 female) completed the follow-up survey (77% response rate). There was no 
evidence of selection bias in those who were followed up; analysis of baseline 
characteristics of the long term follow-up sample demonstrated that it was representative 
of the entire original sample. There were also no significant baseline differences between 
the two treatment groups in the current study (independent-samples t tests, Table 1). 
 
Primary Outcome: 
In the intention-to-treat analysis, the mean number of vertigo attacks in the past 6 months 
at long-term follow-up compared with baseline decreased from 18.3 (SD 15.6) to 1.0 (SD 
2.4) in the gentamicin group (95% reduction, p<0.001, paired t test analysis) and from 16.2 
(SD 13.5) to 0.8 (SD 2.6) in the methylprednisolone group (95% reduction, p<0.001; mean 
difference at follow-up -0.2, 95% CI -1.3 to 1.7). There was no significant difference between 
treatment groups for the number of vertigo attacks over 6 months at baseline, 24 months or 
long-term follow-up (drug p=0.52; drug x time interaction p=0.90, primary outcome), Figure 
1. An independent-samples t test confirmed no significant difference for the number of 
attacks of vertigo over 6 months between the two treatment groups at long-term follow-up 
(p=0.80). 
 
Secondary Outcomes: 
The mean number of vertigo attacks in the past 1 month at long-term follow-up compared 
with baseline decreased in the gentamicin group by 95% and in the methylprednisolone 
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group by 99% (both p<0.001, paired t test analysis). There was no significant difference 
between treatment groups for the number of vertigo attacks over 1 month at baseline, 24 
months or long-term follow-up (drug p=0.73; drug x time interaction p=0.59), Figure 2A. An 
independent-samples t test confirmed no significant difference for the number of attacks of 
vertigo over 1 month between the two treatment groups at long-term follow-up (p=0.85) 
 
No significant difference was found between treatment groups for VSS score (drug p=0.19, 
drug x time interaction p=0.99), DHI score (drug p=0.33, drug x time interaction p=0.98), THI 
score (drug p=0.78, drug x time interaction p=0.93), AFS score (drug p=0.21, drug x time 
interaction p=0.52) and FLS score (drug p=0.27, drug x time interaction p=0.71), Figure 2B-F. 
Independent-samples t tests showed no significant differences between the two treatment 
arms for any of the symptom questionnaires at long-term follow-up.   
 
The per protocol analysis performed for primary and secondary outcomes confirmed the 
results of the intention-to-treat analysis; there were no significant differences between the 
two treatment groups.    
 
Post-trial treatments: 
Between baseline treatment and long-term follow-up, 22/46 patients received additional 
injections. 13/22 patients (59%) in the methylprednisolone group had further injections to 
re-establish vertigo control and 9/24 patients (37%) in the gentamicin group (odds ratio 2.4, 
95% CI 0.74 to 7.88; chi-square p=0.14, Fisher’s exact test p=0.24). From this, 8/46 patients 
had additional injections between 24months and long-term follow-up (i.e., post-trial). 5/22 
patients (23%) had further injections between the 24 month follow-up and long-term 
follow-up in the methylprednisolone group, which included 1 new patient who had not 
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previously required further treatment between baseline and 24 months follow-up, and 3/24 
patients (13%) from the gentamicin group, with 1 new patient (odds ratio 2.1, 95% CI 0.43 to 
9.87; chi-square p=0.36, Fisher’s exact test p=0.45).    
 
No safety concerns about either drug were raised.    
 
 
Discussion 
In this long-term follow-up study, we established that methylprednisolone and gentamicin 
are both equally effective for long-term vertigo control in unilateral refractory Menière’s 
disease. The overall reduction of vertigo attacks at long-term follow-up compared to the 6 
months prior to initial treatment was 95% for both methylprednisolone and gentamicin. 
There were also significant reductions for the secondary outcomes, number of vertigo 
attacks over a 1 month period and audio-vestibular symptom questionnaires, with no 
difference between the two drugs.  
Our aim was to provide robust long-term evidence for the role of ITS treatment in this 
disease. Cochrane published the first systematic review of ITS for Menière’s disease in 2011, 
and at that time only one small placebo controlled study was included, which provided 
limited support to using ITS treatment.22,23 Cochrane reviews of other treatment modalities 
(betahistine, diuretics, positive pressure therapy, endolymphatic sac surgery) have all 
concluded that there is insufficient evidence to support their use.6,24-26 
A literature review of ITS for Menière’s disease was undertaken by one of our co-authors in 
2017.27 12 studies (6 prospective) meeting AAOHNS reporting guidelines were identified, of 
which 8 have been published since the 2011 ITS Cochrane paper. The review found results 
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for over 600 patients treated with ITS (methylprednisolone or dexamethasone, with varying 
doses/protocols, including 8 ‘as needed’ study protocols) reporting median percentage of 
complete vertigo control (AAO-HNS Class A) at 2 years follow-up of 71% (IQR 42-81%). No 
significant reduction of hearing was identified in any study. 
The previous longest follow-up of 8 years was in a retrospective study using 
dexamethasone, which found that there was a plateau of satisfactory vertigo control 
beyond 2 years follow-up.28 To date our study has the longest follow-up reported for 
intratympanic methylprednisolone injection in Menière’s disease and our results support 
these previous findings for dexamethasone. 
In 2017 Masoumi et al. published a randomised trial in 69 patients of intratympanic 
methylprednisolone versus intratympanic dexamethasone. The trial used the AAOHNS 
outcomes criteria for Menieres research. They identified no statistically significant 
difference between vertigo control in the two drug groups, but methylprednisolone showed 
statistically significant hearing improvement.29 
 
 
As we have highlighted the main strengths of this study are the length of follow-up, as well 
as the high response rate of 77% from the original trial participants. Although not reaching 
statistical significance, there was a trend for a higher frequency of repeat injections required 
in the methylprednisolone than in the gentamicin group as perhaps expected. 
 
We acknowledge that there are several limitations with this study, including the absence of 
a placebo arm. It was felt that it would have been unethical to leave patients in the severely 
symptomatic stage of Menière’s Disease untreated for up to 2 years, particularly in view of 
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the 2014 gentamicin Vs placebo RCT which was stopped early and the 2011 Cochrane 
review.30,31  
Similarly, there were ethical reasons for not collecting prospective treatment-free symptom 
diaries in this significantly symptomatic group. The recognised limitation of recall bias which 
this has incurred, both in the retrospective collection of pre-baseline symptoms and the 
post-trial postal-survey reported here has been looked at in a recent paper by authors in our 
group.32 In that study patients with Menière’s Disease were asked to recall the number of 
attacks that they had experienced over 6 months and 1 month, and the number 
recalled was consistent with those produced from the large scale BEMED Menière’s Disease 
intervention trial in which patients used a diary to record disease activity.33 We would also 
argue that any recall bias would affect both drug groups equally, and the original trial and 
long-term follow-up study equally as the same methodology was used throughout. 
 
The number of patients involved in this multicentre trial, and particularly the number 
available for long-term follow-up is not large, but reflects the incidence of this disease and 
the acknowledged response bias difficulties of using mail surveys, despite telephone and 
email contact to those who did not respond initially. Prospective hearing and formal balance 
testing/neurotological clinical examination at long-term follow-up was not in the scope of 
available resources in this unfunded follow-up study. Attempts were made to collect recent 
audiology for patients by contacting their local provider but numbers obtained were too 
small to include in our analysis. Similarly, detailed information about further injections after 
the formal 2 year trial had ended was limited by the patients being recruited nationally and 
thus had follow-up treatment with their local ENT unit. 
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In summary, intratympanic methylprednisolone injections are safe and effective in 
managing refractory Menière’s disease, and provide excellent long-term symptom control. 
The choice between methylprednisolone and gentamicin, two equally effective treatments, 
should be made based on individual patient circumstances and the known long-term risks of 
gentamicin ototoxicity.31,34 
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FIGURES 
 
 
 
 
 
Figure 1. Mean number of attacks of vertigo at Baseline (within the 6 months before 
treatment), at 24 months and at long-term follow up (>48 months). Bars are SDs. 
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 Figure 2: Mean scores for Secondary outcomes (A) Mean number of attacks of vertigo 1 
month before treatment at baseline (B) Vertigo Symptom Scale, (C) Dizziness Handicap 
Inventory, (D) Auditory Fullness Scale, (E) Tinnitus Handicap Scale and (F) Functional Level 
Scale before treatment at Baseline, 24 months and at long-term follow up (>48 months). 
Bars are SDs. 
 18 
